Plain-English translation of NCT06284317 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether durvalumab—an immunotherapy medication that helps your immune system fight cancer—should be given for 12 months after you've had chemotherapy, the same medication, and surgery for early-stage lung cancer. Right now, doctors aren't sure if this extra treatment helps prevent the cancer from coming back. This trial will help answer that question.
Early-stage lung cancer can be treated with chemotherapy, immunotherapy, and surgery, but even after successful surgery, some patients' cancers return. Researchers want to know if continuing this medication after surgery can keep the cancer from coming back longer.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy combined with durvalumab for 3–4 months before surgery. After surgery (if you recover well and there is no spread of cancer), you would be randomly assigned to either receive durvalumab injections every 4 weeks for 12 months or to simply be monitored without additional treatment. You would have regular doctor visits and scans to check how you're doing.
AI-generated summary from trial data · Aug 17, 2026 · Not medical advice
Australia